Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on CervoMed (CRVO) to $19 from $20 and keeps a Buy rating on the shares. In the wake of Q3 financial results, the firm caught up with CervoMed CFO Bill Elder for further insights, the analyst tells investors in a research note. At the end of Q3 the company has roughly $27.3M in cash, which, per management’s view, is expected to fund operations through 3Q26, the analyst notes.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed reports Q3 EPS (84c), consensus (56c)
- CervoMed’s Promising Phase 3 Trial and Strategic Financial Position Support Buy Rating
- CervoMed upgraded to Buy from Neutral at H.C. Wainwright
- CervoMed’s Strategic Phase 3 Trial Progress for Neflamapimod Boosts Buy Rating
- CervoMed announces FDA alignment on neflamapimod registration path